SLC6A4 and major depressive disorder: The development of this protocol will allow us to quickly advance the validation of SERT membrane protein clustering in lymphocytes as a biomarker of therapeutic efficacy in major depression, and facilitate the implementation of this type of analysis in clinical settings.